VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.

VNRX has been the subject of several other research reports. Benchmark reissued a hold rating on shares of VolitionRx in a research report on Friday, August 16th. Cantor Fitzgerald reissued an overweight rating and issued a $2.50 price target on shares of VolitionRx in a report on Thursday, May 16th.

VolitionRx Trading Down 1.1 %

NYSE:VNRX opened at $0.71 on Friday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.38. The firm’s fifty day simple moving average is $0.64 and its 200 day simple moving average is $0.74. The firm has a market capitalization of $65.58 million, a PE ratio of -1.55 and a beta of 1.12.

VolitionRx (NYSE:VNRX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.34 million. As a group, analysts anticipate that VolitionRx will post -0.31 EPS for the current fiscal year.

Insider Activity at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 150,000 shares of the stock in a transaction on Tuesday, August 20th. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the purchase, the director now owns 406,683 shares of the company’s stock, valued at $272,477.61. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 12.80% of the stock is owned by insiders.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.